在高密度脂蛋白上可交换的APOA1抑制低密度脂蛋白与蛋白质糖的结合
Esmond N Geh1, Debi K Swertfeger1, Isabella Roscoe1
1Division of Endocrinology, Cincinnati Children's Hospital Medical Center & the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Journal of lipid research
|August 23, 2025
概括
高密度脂蛋白 (HDL) 通过释放非脂蛋白A1 (APOA1) 预防动脉样硬化,后者会干扰低密度脂蛋白 (LDL) 与动脉蛋白质糖 (PG) 结合. 这种机制减少了LDL在血管中的保留.
科学领域:
- 生物化学
- 心血管生物学
- 分子医学
背景情况:
- 动脉样硬化的发展包括低密度脂蛋白 (LDL) 被动脉壁蛋白质 (PG) 捕获.
- 已知高密度脂蛋白 (HDL) 能调节这一过程,但其确切的机制尚不清楚.
研究的目的:
- 阐明HDL如何抑制动脉细胞外基质 (ECM) 中的LDL与PG的结合.
主要方法:
- 细胞内ELISA测量小鼠血管光滑肌细胞中的LDL-PG结合.
- 生物化学技术包括快速蛋白液色谱,免疫沉,SDS-PAGE和免疫浸泡用于分析HDL和阿波脂蛋白相互作用.
主要成果:
- 显示了对LDL-PG结合的剂量依赖性抑制.
- APOA1 脱离 HDL 并与 LDL 结合,从而降低了 LDL 与 PG 结合的能力.
- 当APOA1与HDL颗粒结合时,HDL的抑制作用被消除.
结论:
- HDL通过其表面的松散附着,无脂质的APOA1来抑制LDL-PG结合.
- 没有脂质的APOA1被确定为降低动脉LDL保留的关键调解剂.
- 这些发现为HDL对动脉样硬化的保护作用提供了新的见解.
相关概念视频
Receptor-mediated Endocytosis
105.7K
Overview
105.7K
Atherosclerosis I: Introduction
77
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
77
Proteoglycans
4.0K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
4.0K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
Lipid Absorption
723
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
723
Factors Affecting Protein-Drug Binding: Drug-Related Factors
195
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
195


